An open-label, multi-center, non-randomized phase I dose escalation study to investigate the safety,tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 given as monotherapy inpatients with relapsed or refractory T-cell Lymphoma

The purpose of this study is to find out the safety, effectiveness, and blood levels of various doses of the study drug in participants with T-cell lymphoma that has not improved or has gotten worse. ONO-4685 is an experimental drug which is not approved by Health Authorities including United States Food and Drug Administration (FDA). The study drug is a protein made in laboratory called an antibody. Antibodies are made naturally in our body and are a key part of our immune system. The study drug antibody targets 2 specific proteins: a protein called PD-1 on cancer cells and protein

Are you Eligible? (Inclusion Criteria)

• Are you 18 years of age or older? Have you been diagnosed with T-cell lymphoma and have had at least 2 previous types of treatment? Are you willing to come to the clinic for additional evaluations and treatments?